Clinical trial · Observational
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
NCT02762448CI-TRIAL-00032584withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no patient enrollment
Summary
Brief summary (as posted)
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis c | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Daclatasvir+ Asunaprevir | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Daclatasvir + Asunaprevir
- description
- Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
- interventionNames
- Drug: Daclatasvir+ Asunaprevir
Primary outcomes (1)
- measure
- HCV clearance and complete regression of NHL by ASV+ DCV
- timeFrame
- 2years
- description
- patients who had undetectable HCV RNA levels at or after week 4. Viral relapse was defined as confirmed detectable HCV RNA levels during the post-treatment follow-up period in patients who had had undetectable HCV RNA levels at the end of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Men and women 2. 18 to 70 years of age 3. Who had chronic HCV genotype 1b infection 4. An HCV RNA level of 105 IU per milliliter or higher 5. Being diagnosed to be low grade B cell non-Hodgkin lymphoma Exclusion Criteria: 1. Patients with hepatitis B virus infection, 2. Other liver diseases 3. HIV infection, 4. Pre-existing HCV variants in the NS5A domain included Q30R, L31 M/V, and Y93C/N 5. Evidence of cirrhosis, as documented by means of either liver biopsy or assessment of imaging results.
References
Publications (0)
Data not yet available
No reference posted for this study.